Can patients with thrombocytopenia be cured by taking avatrombopag/sucosin?

Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA), mainly used to treat chronic immune thrombocytopenia (ITP) and thrombocytopenia caused by chronic liver disease. Many patients are concerned about whether this drug can truly "cure" thrombocytopenia. In fact, from the current medical understanding, avatrombopag cannot completely cure this type of disease. Its main function is to stimulate the maturation of megakaryocytes and platelet production in the bone marrow, thereby increasing the patient's platelet level within a certain period of time, reducing the risk of bleeding, and improving the quality of daily life.

Thrombocytopenia is a complex hematological disease that often involves multiple factors such as immune system abnormalities, liver disease or drug-induced injury, resulting in the body's inability to maintain stable platelet production. The application value of avatrombopag is that it is different from traditional blood transfusions or glucocorticoids. Instead, it starts from the source of platelet production and can maintain long-term effective platelet levels through oral medication, which has greatly changed the treatment landscape of thrombocytopenia. However, due to the complex disease mechanism and large individual differences among patients, relying solely on avatrombopag cannot completely eradicate the root cause of the disease. Therefore, clinical practice often emphasizes "control and maintenance" rather than "cure".

In overseas medical guidelines, avatrombopag is recommended as one of the important options for long-term management of ITP. It is safe and operable. It is a relatively ideal alternative, especially for patients who are not suitable for repeated blood transfusions or who cannot tolerate the side effects of hormones. It needs to be emphasized that patients should regularly monitor platelet levels while taking it and adjust the dosage under the guidance of a doctor to avoid the risk of blood clots caused by excessive platelet elevation.

Reference materials:https://go.drugbank.com/drugs/DB11995